🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, -, PACLITAXEL , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-2870, MK-2870, DOXORUBICIN , CAPECITABINE , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE , PARACETAMOL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  3. -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CAPECITABINE , PARACETAMOL , MK-2870, DEXAMETHASONE

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  4. -, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MK-2870, Avastin 25 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  5. -, PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., MK-2870, MVASI 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., CISPLATIN

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  6. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  8. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  9. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  10. 5% Dextrose injection; Solution for injection/infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% Sodium Chloride injection; Solution for injection/infusion

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  11. 5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion

    The George Institute

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  12. ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  13. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  14. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  15. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  16. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  18. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  20. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Lacuna Pharma Pty Ltd

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  21. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN , PEMBROLIZUMAB, CARBOPLATIN , PACLITAXEL , PEMETREXED

    Fondazione Telethon ETS

    metastatic NSCLC patients

    phase 3 small molecule active

    1 trial

  23. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  24. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources